Navitoclax is known to induce dose-limiting thrombocytopenia, which has been attributed to its targeting of BCL-XL [67], yet intermittend or lower navitoclax dosing [70] and novel dual BCL-2-/BCL-XL [71] inhibitors show promising clinical potential, as these strategies may provide better tolerance. This evidence concerns the gene BCL2 and Thrombocytopenia.